Refine by
Immune Oncology Suppliers & Manufacturers
17 companies found
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
based inBremen, GERMANY
OMNI Life Science provides cutting edge solutions for cell research. Focusing on people and innovations throughout, our mission is to promote research in Life Sciences with smart, reliable and user-friendly technology. We are highly specialized on ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our ...
based inCambridge, MASSACHUSETTS (USA)
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, ...
based inEpalinges, SWITZERLAND
AC BioScience Ltd., a clinical-stage biotech company and a developer of immune modulating and angiogenic cancer therapies. AC BioScience LTD. is a Swiss biotech company, pioneering the development of novel therapies in immuno-oncology and tumor ...
based inBaldham, GERMANY
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ...
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, ...
based inRapperswil, SWITZERLAND
Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders. ...
We are looking to expand our portfolio of products with novel life-transforming therapies that address severe unmet medical needs in particular in the areas of transplantation, hemato-oncology, and immune ...
based inHilden, GERMANY
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins ...
based inOxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
A universal donor cell is a kind of cell that can be used for transplantation into anyone. In other words, it is a cell in which the induction of immune rejection*１ (Human Leukocyte ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
Cancer immunology, or “immuno-oncology,” is a growing field of research that aims to discover innovative cancer immunotherapies to treat and impede the progression of the disease. Understanding how cancer evades the ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...